News
22/06/2022

Medical biotech report shows thriving sector, treatment advances

Germany’s medical biotechnology industry is continuing to grow in all areas according to a report by the Boston Consulting Group (BCG). At the same time, the survey analyzed the positive impact medical biotechnology is having on developing treatments for rare diseases.

Forscherin arbeitet im Labor
© istockphoto.com/ AlexRaths

Medical biotech sales (pharmacies and hospitals) increased by 10.2 percent to EUR 16.1 billion in 2021, said BCG. In terms of the sector’s share of the pharmaceuticals market as a whole, BCG noted a slight increase – from 30.8 percent to 31.4 percent in all areas of medical application. Meanwhile, said BCG, these figures exclude turnovers from SARS-CoV-2. The consulting group estimated this sum to have been as much as EUR 2.5 billion in 2021.

The report added that within a year after approval, biosimilars attain significant market shares of up to 80 percent. What is more, the report said there were 26 newly approved biopharmaceuticals, with medical biotechnology accounting for nearly half (46 percent) of all new drugs.

Commissioned by vfa-bio and entitled Medizinische Biotechnologie in Deutschland 2022, the report noted that the pipeline for new products grew by 1.8 percent despite the challenges caused by the pandemic. It also said the number of products in clinical development stages increased last year from 657 to 669. Medical biotechnology continued to be a job generator as well, said the BCG, with the sector employing a record 46 thousand people after the number of positions grew by 3.1 percent in 2021.

The report’s analysis of “orphan drugs,” said that of 200 products that have been approved for market, around 30 percent are biopharmaceuticals. These drugs are used in a range of areas, but particularly for rare types of cancer of metabolic diseases.

These latest figures demonstrate the dynamism of Germany’s medical biotechnology sector. Vfa-bio represents the biotechnology interests of the Association of Research-Based Pharmaceuticals Companies (vfa). The vfa and vfa-bio are members of HEALTH MADE IN GERMANY’s working groups, making it the go-to organization when it comes to learning more about doing business in these fields in Germany. HEALTH MADE IN GERMANY has published profiles and directories as well as a film on medical biotechnology.